Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of apitegromab in type 2 and type 3 spinal muscular atrophy
NL-OMON53608Phase 3Recruiting
- Sponsor
- Scholar Rock
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apitegromab in spinal muscular atrophy (SMA), sponsored by Scholar Rock. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events by severity. Started Nov 2023; status: recruiting.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON53608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53608.